Revisiting TSCPC as an option

Article

Procedure has ability to lower IOP, preserve vision similar to trabeculectomy and tube shunts

Blebless ab externo glaucoma surgeries, which include canaloplasty and deep sclerectomy, are successful at lowering high IOP while still maintaining a good safety profile. Filtering surgeries, such as trabeculectomy, ExPRESS shunt (Alcon Laboratories, Fort Worth, Texas, USA), and tubes, are the go-to options when a patient requires an IOP lower than 10 to 12 mmHg.

Transscleral cyclophotocoagulation (TSCPC) has typically been reserved for patients with little hope of maintaining their vision. The American Academy of Ophthalmology Ophthalmic Technology Assessment Committee stated, "Cyclophotocoagulation is indicated for patients with refractory glaucoma who have failed trabeculectomy or tube shunt procedures, patients with minimal useful vision and elevated IOP, patients who have no visual potential and need pain relief, and patients with complicated glaucoma and conjunctival scarring from previous surgery."1

New techniques, such as the slow coagulation method by Doug Gaasterland, are making TSCPC safer. This approach uses a lower amount of energy over a longer duration of time, leaving the eyes quieter, and it reduces some of the complications, such as inflammation, uveitis and cystoid macular oedema.

On the cusp of development is a MicroPulse CPC procedure, which is believed will further enhance safety and allow more comfort in using the procedure earlier in the treatment paradigm. In addition, the use of steroids and non-steroidal anti-inflammatory drugs perioperatively has helped mitigate some of the complications.

A glaucoma device (G-Probe, Iridex, Mountain View, California, USA) is designed to direct infrared energy toward the ciliary body and I tend to err on the side of posterior placement as well. In highly myopic eyes, I often use transillumination to identify the exact location of the ciliary body. This technique is effective anytime extra confidence is needed with where to direct the laser and more precise targeting of the ciliary processes can reduce pain and inflammation after the procedure.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.